Roche is facing an early expiry of the UK supplementary protection certificate (SPC) for its ophthalmology drug, Lucentis (ranibizumab), after its duration was shortened by nearly two years because of an administrative error.
The term of the SPC, which was granted to the Roche subsidiary Genentech, should have been three years and nine...






